Cellular Therapy for Autoimmune Disease

Erscheinungsjahr 2027
ISBN: 978-0-443-43978-0
Verlag: Elsevier Science

Buch, Englisch, 250 Seiten, Format (B × H): 191 mm x 235 mm, Gewicht: 449 g

Cellular Therapy for Autoimmune Disease provides a comprehensive exploration of the evolving landscape of cellular therapies for autoimmune diseases. The book delves into the evolution of the standard of care for autoimmune diseases, transitioning from chronic suppression to targeted replacement or suppression therapies. It covers a wide array of topics, including stem cell transplants, B-cell and plasma cell depletion strategies, and autologous regulatory and effector T-cell approaches. Additionally, it explores myeloid cellular approaches, allogeneic cellular therapies, and viral or nanoparticle-based strategies. Each chapter provides a thorough examination of mechanisms of action, clinical and non-clinical data, and the associated risks and benefits.

Finally, the book addresses unique clinical and manufacturing considerations, offering a roadmap for the future state of cellular therapies in autoimmune diseases. This essential resource addresses the rapid advancements in cell therapies that have outpaced the availability of integrated, up-to-date resources. By bridging the gap between scientific research and clinical applications, it offers in-depth insights into mechanisms of action, disease-specific therapeutic strategies, and the latest innovations in clinical and manufacturing considerations for scientists and clinicians.

Autoren/Hrsg.

Basu, Samik

Lee, Jinmin

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie

Inhaltsverzeichnis

1. How the standard of care for autoimmune diseases has evolved from chronic suppression to that of targeted replacement or suppression
2. Autologous Regulatory T-cell (Treg) approaches for autoimmune disease
3. Autologous Effector T-cell approaches for autoimmune disease. Part I, Antigen Specific Approaches
4. Autologous Effector T-cell approaches for autoimmune disease. Part II, Pan B-cell Depletion Approaches
5. Autologous Effector T-cell approaches for autoimmune disease. Part III, Pan Plasma Cell Depletion Approaches
6. Myeloid Cellular Approaches for Autoimmune Disease
7. Allogeneic Cellular Approaches for Autoimmune Disease
8. Viral or Nanoparticle-Based Approaches for Autoimmune Disease
9. Unique Clinical Considerations for Cellular Therapies for Autoimmune Disease
10. Unique Manufacturing Considerations for Cellular Therapies for Autoimmune Disease
11. Global Perspectives. Regulatory, Ethical, and Cultural Dimensions of Cellular Therapies
12. Future Directions and Challenges for Cellular Therapies in Autoimmune Disease

Über Autor(innen)

Lee, Jinmin
Dr. Jinmin Lee joined Cabaletta in November 2019 and currently serves as the Head of Cellular and Molecular Immunology at Cabaletta, where she leads preclinical research efforts on developing cell therapies for autoimmune diseases. Prior to joining Cabaletta, her research focused on cell therapy for targeted depletion of autoreactive B cells in autoimmune diseases, and fundamental B cell biology including mechanisms of naïve and memory B cell activation. She has over 10 years of industry and academic experience in cellular immunology, cell therapy, and autoimmunity with prior roles at the National Institutes of Health and the University of Pennsylvania. Dr. Lee earned her Ph.D. degree in Immunology from Cornell University, followed by postdoctoral training at the National Institute of Allergy and Infectious Diseases and the University of Pennsylvania.

Basu, Samik
Dr. Samik Basu joined Cabaletta in December 2019 and recently became Chief Scientific Officer, previously serving as Vice President of Preclinical Research and Translational Medicine. Before Cabaletta, he was Head of Translational Sciences at Adaptimmune Therapeutics, Plc, leading research on TCR-based adoptive immunotherapies. At Merck Research Laboratories, he co-led preclinical development for Keytruda (pembrolizumab). With over 15 years of industry and academic experience, Dr. Basu has held roles at the NIH, Albert Einstein College of Medicine, and the University of Pennsylvania. He earned his M.D. from Temple University and completed residency in Clinical Pathology. Dr. Basu chairs the Clinical Immunology Committee of the American Association of Immunologists and has authored over 15 peer-reviewed articles.